Cell culture in immune cell therapies: do more with less

Anastasiya Smith, Josh Ludwig, David Hermanson

08 June 2023

Expert Roundtable

Accelerating cancer therapies development: the importance of platform, process, and partnership

William Swaney, John (Yoshi) Shyu, Nikhil Tyagi

22 April 2023

Expert Roundtable

Autologous versus allogeneic: the future of manufacturing and standardization in cell therapies

Rupa Pike, Delara Motlagh, Patrick Hanley

05 October 2022

Expert Roundtable

Expert Roundtable: accelerating time to market for CAR-T cell therapies through translatable workflow

Tariq Haq

22 November 2021

Expert Roundtable

Expert Roundtable: leveraging cutting edge tools to convert I-O data into knowledge

A K Sood, S Prabhakaran, G Goldmacher et al

12 October 2021

Expert Roundtable

Enhancing preclinical predictivity in I-O: what is going wrong between preclinical in vitro/in vivo and clinical settings?

05 August 2021

Expert Roundtable

Hunting for better biomarkers of response: where is real progress being made in understanding why patients do and don’t respond to I-O therapeutics?

09 June 2021

Expert Roundtable

How to increase I-O manufacturing efficiency, flexibility, and productivity in line with expected future trends in supply and demand?

John Lunger

23 April 2021

Expert Roundtable

Expert Roundtable: Clinical success of checkpoint inhibitors: what's next for combination therapy in I-O?

J J Luke, J Fairchild , R Taylor et al

11 November 2020

Expert Roundtable

Immuno-oncology manufacturing: progress towards streamlined commercialization

A Davies, Ø Åmellem, K Niss et al

13 August 2019

Expert Roundtable

Gaining critical characterization insights for development of CAR-T therapies for solid tumors

S Kassim, J Krishnamurthy, T Laskowski et al

29 July 2019

Expert Roundtable